---
document_datetime: 2025-12-02 05:24:02
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/telmisartan-teva.html
document_name: telmisartan-teva.html
version: success
processing_time: 0.125134
conversion_datetime: 2025-12-27 14:40:43.726422
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Telmisartan Teva

[RSS](/en/individual-human-medicine.xml/66278)

##### Withdrawn

This medicine's authorisation has been withdrawn

telmisartan Medicine Human Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Telmisartan Teva](#news-on)
- [More information on Telmisartan Teva](#more-information-on-telmisartan-teva-1254)
- [More information on Telmisartan Teva](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 19 May 2021, the European Commission withdrew the marketing authorisation for Telmisartan Teva (telmisartan) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Teva B.V., which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Telmisartan Teva was granted marketing authorisation in the EU on 26 January 2010 for the treatment of essential hypertension. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2014.

Telmisartan Teva is a generic medicine of Micardis. There are other generic medicinal products of Micardis authorised and marketed in the EU.

The European Public Assessment Report (EPAR) for Telmisartan Teva is updated to indicate that the marketing authorisation is no longer valid.

Telmisartan Teva : EPAR - Summary for the public

English (EN) (646.62 KB - PDF)

**First published:** 22/03/2010

**Last updated:** 26/06/2015

[View](/en/documents/overview/telmisartan-teva-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-880)

български (BG) (1.89 MB - PDF)

**First published:**

22/03/2010

**Last updated:**

26/06/2015

[View](/bg/documents/overview/telmisartan-teva-epar-summary-public_bg.pdf)

español (ES) (1.2 MB - PDF)

**First published:**

22/03/2010

**Last updated:**

26/06/2015

[View](/es/documents/overview/telmisartan-teva-epar-summary-public_es.pdf)

čeština (CS) (1.27 MB - PDF)

**First published:**

22/03/2010

**Last updated:**

26/06/2015

[View](/cs/documents/overview/telmisartan-teva-epar-summary-public_cs.pdf)

dansk (DA) (1.2 MB - PDF)

**First published:**

22/03/2010

**Last updated:**

26/06/2015

[View](/da/documents/overview/telmisartan-teva-epar-summary-public_da.pdf)

Deutsch (DE) (1.2 MB - PDF)

**First published:**

22/03/2010

**Last updated:**

26/06/2015

[View](/de/documents/overview/telmisartan-teva-epar-summary-public_de.pdf)

eesti keel (ET) (1.22 MB - PDF)

**First published:**

22/03/2010

**Last updated:**

26/06/2015

[View](/et/documents/overview/telmisartan-teva-epar-summary-public_et.pdf)

ελληνικά (EL) (1.3 MB - PDF)

**First published:**

22/03/2010

**Last updated:**

26/06/2015

[View](/el/documents/overview/telmisartan-teva-epar-summary-public_el.pdf)

français (FR) (1.2 MB - PDF)

**First published:**

22/03/2010

**Last updated:**

26/06/2015

[View](/fr/documents/overview/telmisartan-teva-epar-summary-public_fr.pdf)

hrvatski (HR) (1.75 MB - PDF)

**First published:**

22/03/2010

**Last updated:**

26/06/2015

[View](/hr/documents/overview/telmisartan-teva-epar-summary-public_hr.pdf)

italiano (IT) (1.2 MB - PDF)

**First published:**

22/03/2010

**Last updated:**

26/06/2015

[View](/it/documents/overview/telmisartan-teva-epar-summary-public_it.pdf)

latviešu valoda (LV) (1.25 MB - PDF)

**First published:**

22/03/2010

**Last updated:**

26/06/2015

[View](/lv/documents/overview/telmisartan-teva-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (1.22 MB - PDF)

**First published:**

22/03/2010

**Last updated:**

26/06/2015

[View](/lt/documents/overview/telmisartan-teva-epar-summary-public_lt.pdf)

magyar (HU) (1.27 MB - PDF)

**First published:**

22/03/2010

**Last updated:**

26/06/2015

[View](/hu/documents/overview/telmisartan-teva-epar-summary-public_hu.pdf)

Malti (MT) (1.26 MB - PDF)

**First published:**

22/03/2010

**Last updated:**

26/06/2015

[View](/mt/documents/overview/telmisartan-teva-epar-summary-public_mt.pdf)

Nederlands (NL) (1.2 MB - PDF)

**First published:**

22/03/2010

**Last updated:**

26/06/2015

[View](/nl/documents/overview/telmisartan-teva-epar-summary-public_nl.pdf)

polski (PL) (1.28 MB - PDF)

**First published:**

22/03/2010

**Last updated:**

26/06/2015

[View](/pl/documents/overview/telmisartan-teva-epar-summary-public_pl.pdf)

português (PT) (1.2 MB - PDF)

**First published:**

22/03/2010

**Last updated:**

26/06/2015

[View](/pt/documents/overview/telmisartan-teva-epar-summary-public_pt.pdf)

română (RO) (1.25 MB - PDF)

**First published:**

22/03/2010

**Last updated:**

26/06/2015

[View](/ro/documents/overview/telmisartan-teva-epar-summary-public_ro.pdf)

slovenčina (SK) (1.26 MB - PDF)

**First published:**

22/03/2010

**Last updated:**

26/06/2015

[View](/sk/documents/overview/telmisartan-teva-epar-summary-public_sk.pdf)

slovenščina (SL) (1.25 MB - PDF)

**First published:**

22/03/2010

**Last updated:**

26/06/2015

[View](/sl/documents/overview/telmisartan-teva-epar-summary-public_sl.pdf)

Suomi (FI) (1.2 MB - PDF)

**First published:**

22/03/2010

**Last updated:**

26/06/2015

[View](/fi/documents/overview/telmisartan-teva-epar-summary-public_fi.pdf)

svenska (SV) (1.2 MB - PDF)

**First published:**

22/03/2010

**Last updated:**

26/06/2015

[View](/sv/documents/overview/telmisartan-teva-epar-summary-public_sv.pdf)

## Product information

Telmisartan Teva : EPAR - Product Information

English (EN) (1.14 MB - PDF)

**First published:** 22/03/2010

**Last updated:** 25/03/2021

[View](/en/documents/product-information/telmisartan-teva-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-109)

български (BG) (3.71 MB - PDF)

**First published:**

22/03/2010

**Last updated:**

25/03/2021

[View](/bg/documents/product-information/telmisartan-teva-epar-product-information_bg.pdf)

español (ES) (2.07 MB - PDF)

**First published:**

22/03/2010

**Last updated:**

25/03/2021

[View](/es/documents/product-information/telmisartan-teva-epar-product-information_es.pdf)

čeština (CS) (3.22 MB - PDF)

**First published:**

22/03/2010

**Last updated:**

25/03/2021

[View](/cs/documents/product-information/telmisartan-teva-epar-product-information_cs.pdf)

dansk (DA) (2.02 MB - PDF)

**First published:**

22/03/2010

**Last updated:**

25/03/2021

[View](/da/documents/product-information/telmisartan-teva-epar-product-information_da.pdf)

Deutsch (DE) (2.08 MB - PDF)

**First published:**

22/03/2010

**Last updated:**

25/03/2021

[View](/de/documents/product-information/telmisartan-teva-epar-product-information_de.pdf)

eesti keel (ET) (2.1 MB - PDF)

**First published:**

22/03/2010

**Last updated:**

25/03/2021

[View](/et/documents/product-information/telmisartan-teva-epar-product-information_et.pdf)

ελληνικά (EL) (3.82 MB - PDF)

**First published:**

22/03/2010

**Last updated:**

25/03/2021

[View](/el/documents/product-information/telmisartan-teva-epar-product-information_el.pdf)

français (FR) (2.1 MB - PDF)

**First published:**

22/03/2010

**Last updated:**

25/03/2021

[View](/fr/documents/product-information/telmisartan-teva-epar-product-information_fr.pdf)

hrvatski (HR) (2.27 MB - PDF)

**First published:**

22/03/2010

**Last updated:**

25/03/2021

[View](/hr/documents/product-information/telmisartan-teva-epar-product-information_hr.pdf)

íslenska (IS) (2.01 MB - PDF)

**First published:**

22/03/2010

**Last updated:**

25/03/2021

[View](/is/documents/product-information/telmisartan-teva-epar-product-information_is.pdf)

italiano (IT) (2.04 MB - PDF)

**First published:**

22/03/2010

**Last updated:**

25/03/2021

[View](/it/documents/product-information/telmisartan-teva-epar-product-information_it.pdf)

latviešu valoda (LV) (3.48 MB - PDF)

**First published:**

22/03/2010

**Last updated:**

25/03/2021

[View](/lv/documents/product-information/telmisartan-teva-epar-product-information_lv.pdf)

lietuvių kalba (LT) (2.17 MB - PDF)

**First published:**

22/03/2010

**Last updated:**

25/03/2021

[View](/lt/documents/product-information/telmisartan-teva-epar-product-information_lt.pdf)

magyar (HU) (3.2 MB - PDF)

**First published:**

22/03/2010

**Last updated:**

25/03/2021

[View](/hu/documents/product-information/telmisartan-teva-epar-product-information_hu.pdf)

Malti (MT) (3.36 MB - PDF)

**First published:**

22/03/2010

**Last updated:**

25/03/2021

[View](/mt/documents/product-information/telmisartan-teva-epar-product-information_mt.pdf)

Nederlands (NL) (2.07 MB - PDF)

**First published:**

22/03/2010

**Last updated:**

25/03/2021

[View](/nl/documents/product-information/telmisartan-teva-epar-product-information_nl.pdf)

norsk (NO) (2.02 MB - PDF)

**First published:**

22/03/2010

**Last updated:**

25/03/2021

[View](/no/documents/product-information/telmisartan-teva-epar-product-information_no.pdf)

polski (PL) (3.27 MB - PDF)

**First published:**

22/03/2010

**Last updated:**

25/03/2021

[View](/pl/documents/product-information/telmisartan-teva-epar-product-information_pl.pdf)

português (PT) (2.07 MB - PDF)

**First published:**

22/03/2010

**Last updated:**

25/03/2021

[View](/pt/documents/product-information/telmisartan-teva-epar-product-information_pt.pdf)

română (RO) (2.2 MB - PDF)

**First published:**

22/03/2010

**Last updated:**

25/03/2021

[View](/ro/documents/product-information/telmisartan-teva-epar-product-information_ro.pdf)

slovenčina (SK) (3.22 MB - PDF)

**First published:**

22/03/2010

**Last updated:**

25/03/2021

[View](/sk/documents/product-information/telmisartan-teva-epar-product-information_sk.pdf)

slovenščina (SL) (3.09 MB - PDF)

**First published:**

22/03/2010

**Last updated:**

25/03/2021

[View](/sl/documents/product-information/telmisartan-teva-epar-product-information_sl.pdf)

Suomi (FI) (2.02 MB - PDF)

**First published:**

22/03/2010

**Last updated:**

25/03/2021

[View](/fi/documents/product-information/telmisartan-teva-epar-product-information_fi.pdf)

svenska (SV) (2.02 MB - PDF)

**First published:**

22/03/2010

**Last updated:**

25/03/2021

[View](/sv/documents/product-information/telmisartan-teva-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IA/0027 09/02/2021

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Telmisartan Teva : EPAR - All Authorised presentations

English (EN) (581.99 KB - PDF)

**First published:** 22/03/2010

**Last updated:** 09/08/2012

[View](/en/documents/all-authorised-presentations/telmisartan-teva-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-899)

български (BG) (1.31 MB - PDF)

**First published:**

22/03/2010

**Last updated:**

09/08/2012

[View](/bg/documents/all-authorised-presentations/telmisartan-teva-epar-all-authorised-presentations_bg.pdf)

español (ES) (1.13 MB - PDF)

**First published:**

22/03/2010

**Last updated:**

09/08/2012

[View](/es/documents/all-authorised-presentations/telmisartan-teva-epar-all-authorised-presentations_es.pdf)

čeština (CS) (1.21 MB - PDF)

**First published:**

22/03/2010

**Last updated:**

09/08/2012

[View](/cs/documents/all-authorised-presentations/telmisartan-teva-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (1.13 MB - PDF)

**First published:**

22/03/2010

**Last updated:**

09/08/2012

[View](/da/documents/all-authorised-presentations/telmisartan-teva-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (1.13 MB - PDF)

**First published:**

22/03/2010

**Last updated:**

09/08/2012

[View](/de/documents/all-authorised-presentations/telmisartan-teva-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (1.13 MB - PDF)

**First published:**

22/03/2010

**Last updated:**

09/08/2012

[View](/et/documents/all-authorised-presentations/telmisartan-teva-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (1.25 MB - PDF)

**First published:**

22/03/2010

**Last updated:**

09/08/2012

[View](/el/documents/all-authorised-presentations/telmisartan-teva-epar-all-authorised-presentations_el.pdf)

français (FR) (1.13 MB - PDF)

**First published:**

22/03/2010

**Last updated:**

09/08/2012

[View](/fr/documents/all-authorised-presentations/telmisartan-teva-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (657.35 KB - PDF)

**First published:**

22/03/2010

**Last updated:**

09/08/2012

[View](/hr/documents/all-authorised-presentations/telmisartan-teva-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (1.13 MB - PDF)

**First published:**

22/03/2010

**Last updated:**

09/08/2012

[View](/is/documents/all-authorised-presentations/telmisartan-teva-epar-all-authorised-presentations_is.pdf)

italiano (IT) (1.13 MB - PDF)

**First published:**

22/03/2010

**Last updated:**

09/08/2012

[View](/it/documents/all-authorised-presentations/telmisartan-teva-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (1.21 MB - PDF)

**First published:**

22/03/2010

**Last updated:**

09/08/2012

[View](/lv/documents/all-authorised-presentations/telmisartan-teva-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (1.17 MB - PDF)

**First published:**

22/03/2010

**Last updated:**

09/08/2012

[View](/lt/documents/all-authorised-presentations/telmisartan-teva-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (1.24 MB - PDF)

**First published:**

22/03/2010

**Last updated:**

09/08/2012

[View](/hu/documents/all-authorised-presentations/telmisartan-teva-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (1.22 MB - PDF)

**First published:**

22/03/2010

**Last updated:**

09/08/2012

[View](/mt/documents/all-authorised-presentations/telmisartan-teva-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (1.13 MB - PDF)

**First published:**

22/03/2010

**Last updated:**

09/08/2012

[View](/nl/documents/all-authorised-presentations/telmisartan-teva-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (1.13 MB - PDF)

**First published:**

22/03/2010

**Last updated:**

09/08/2012

[View](/no/documents/all-authorised-presentations/telmisartan-teva-epar-all-authorised-presentations_no.pdf)

polski (PL) (1.22 MB - PDF)

**First published:**

22/03/2010

**Last updated:**

09/08/2012

[View](/pl/documents/all-authorised-presentations/telmisartan-teva-epar-all-authorised-presentations_pl.pdf)

português (PT) (1.13 MB - PDF)

**First published:**

22/03/2010

**Last updated:**

09/08/2012

[View](/pt/documents/all-authorised-presentations/telmisartan-teva-epar-all-authorised-presentations_pt.pdf)

română (RO) (1.16 MB - PDF)

**First published:**

22/03/2010

**Last updated:**

09/08/2012

[View](/ro/documents/all-authorised-presentations/telmisartan-teva-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (1.22 MB - PDF)

**First published:**

22/03/2010

**Last updated:**

09/08/2012

[View](/sk/documents/all-authorised-presentations/telmisartan-teva-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (1.2 MB - PDF)

**First published:**

22/03/2010

**Last updated:**

09/08/2012

[View](/sl/documents/all-authorised-presentations/telmisartan-teva-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (1.13 MB - PDF)

**First published:**

22/03/2010

**Last updated:**

09/08/2012

[View](/fi/documents/all-authorised-presentations/telmisartan-teva-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (1.13 MB - PDF)

**First published:**

22/03/2010

**Last updated:**

09/08/2012

[View](/sv/documents/all-authorised-presentations/telmisartan-teva-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Telmisartan Teva Active substance telmisartan International non-proprietary name (INN) or common name telmisartan Therapeutic area (MeSH) Hypertension Anatomical therapeutic chemical (ATC) code C09CA07

### Pharmacotherapeutic group

Agents acting on the renin-angiotensin system

### Therapeutic indication

Treatment of essential hypertension in adults

## Authorisation details

EMA product number EMEA/H/C/001146

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Teva B.V.

Swensweg 5

Opinion adopted 19/11/2009 Marketing authorisation issued 25/01/2010 Revision 11

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Telmisartan Teva : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (765 KB - PDF)

**First published:** 01/07/2011

**Last updated:** 25/03/2021

[View](/en/documents/procedural-steps-after/telmisartan-teva-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

Telmisartan Teva-H-C-1146-A31-0010 : EPAR - Scientific conclusions, grounds for variation to the terms of the marketing authorisations and detailed explanation of the scientific grounds for the differences from the PRAC recommendation

English (EN) (609.6 KB - PDF)

**First published:** 25/09/2014

**Last updated:** 25/09/2014

[View](/en/documents/scientific-conclusion/telmisartan-teva-h-c-1146-a31-0010-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendation_en.pdf)

Telmisartan Teva-H-C-1146-A31-0010 : EPAR - Assessment Report - Article 31

Adopted

Reference Number: EMA/PRAC/294920/2014

English (EN) (1.07 MB - PDF)

**First published:** 25/09/2014

**Last updated:** 25/09/2014

[View](/en/documents/variation-report/telmisartan-teva-h-c-1146-a31-0010-epar-assessment-report-article-31_en.pdf)

## Initial marketing authorisation documents

Telmisartan Teva : EPAR - Public assessment report

English (EN) (939.21 KB - PDF)

**First published:** 22/03/2010

**Last updated:** 22/03/2010

[View](/en/documents/assessment-report/telmisartan-teva-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Telmisartan Teva

Adopted

Reference Number: EMEA/CHMP/267262/2009

English (EN) (638.36 KB - PDF)

**First published:** 19/11/2009

**Last updated:** 19/11/2009

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-telmisartan-teva_en.pdf)

#### News on Telmisartan Teva

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 13-16 May 2013](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-13-16-may-2013) 17/05/2013

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 October 2011](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-october-2011) 21/10/2011

[European Medicines Agency concludes that benefit-risk balance of angiotensin-II-receptor antagonists remains positive](/en/news/european-medicines-agency-concludes-benefit-risk-balance-angiotensin-ii-receptor-antagonists-remains-positive) 20/10/2011

#### More information on Telmisartan Teva

Questions and answers on the review of angiotensin-II-receptor antagonists and the risk of cancer

Reference Number: EMA/CHMP/834168/2011

English (EN) (511.41 KB - PDF)

**First published:** 20/10/2011

**Last updated:** 11/05/2017

[View](/en/documents/opinion-any-scientific-matter/questions-answers-review-angiotensin-ii-receptor-antagonists-risk-cancer_en.pdf)

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-211)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### More information on Telmisartan Teva

- [Renin-angiotensin-system (RAS)-acting agents - referral](/en/medicines/human/referrals/renin-angiotensin-system-ras-acting-agents)

**This page was last updated on** 17/09/2021

## Share this page

[Back to top](#main-content)